ZYUS Life Sciences Corporation Secures Unsecured Loan
ZYUS Life Sciences Corporation (TSX-V: ZYUS), a Canadian-based life sciences company, is excited to share the recent conclusion of a CAD$2,000,000 unsecured loan to bolster its mission of developing cannabinoid-based pharmaceutical candidates focused on pain management. An independent director of the Company, referred to as the Lender, facilitated this advancement, providing the financial support needed for ongoing projects. The loan process was subject to proper filing with the TSX Venture Exchange.
Details of the Unsecured Loan
This unsecured loan features a competitive annual interest rate of 12%, which is payable on maturity. ZYUS has the flexibility to pre-pay the loan without incurring penalties, which allows for strategic financial management as needed. The loan matures at the earlier of June 20, 2025, or upon the successful completion of a treasury offering that generates at least CAD$10,000,000. This loan is intended to be utilized for essential working capital purposes to support the company's innovative endeavors.
Amendments to the Secured Promissory Note
In conjunction with this financing, ZYUS has also amended a secured promissory note issued by its subsidiary, ZYUS Life Sciences Inc., which previously dated back to March 21, 2021. This modification updates the note’s principal amount to around CAD$4 million with adjustments made to the interest rate, increasing it from 7% to 12% per annum while extending the maturity date to December 31, 2025. The adjustments to the Promissory Note were made to align with current financial strategies.
Insights on Related Party Transactions
It's important to mention that both the Loan and Promissory Note Amendment fall under the classification of related party transactions. With directors involved in both transactions, transparency remains a priority. Both the Lender and the Company’s CEO, Brent Zettl, who owns the funding entity, abstained from participating in the approval votes for these financial changes, ensuring ethical compliance.
Regulatory Framework and Approvals
ZYUS has utilized the exemptions available through Multilateral Instrument 61-101, allowing it to proceed without a formal valuation or required minority shareholder approval, ensuring that these transactions adhere to securities laws. By not filing a material change report prior to the recent transactions, ZYUS remains committed to transparency while keeping their shareholders informed about significant developments.
Commitment to Innovation
As ZYUS progresses in the development of cannabinoid-based pharmaceuticals, the company remains dedicated to advancing alternatives to traditional pain management therapies, particularly opioids. With rigorous scientific research and intellectual property strategies, ZYUS aims to enhance the quality of life for patients while also building shareholder value. The commitment to non-opioid solutions reflects the broader shift in the industry toward providing safer and more effective treatments.
About ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation is committed to innovating within the life sciences sector. By focusing on cannabinoid-based therapeutic solutions, ZYUS leverages clinical research to secure patents for its unique drugs. With a goal of transforming pain management practices, ZYUS collaborates with regulators to gain approval for its novel pharmaceutical products. For further details about their initiatives and developments, visit their official website or follow them on social media for updates.
Frequently Asked Questions
What is the significance of the CAD$2,000,000 unsecured loan?
This loan is crucial for ZYUS Life Sciences to fund their ongoing research and development efforts in cannabinoid-based pharmaceuticals.
How does the amendment of the secured promissory note impact ZYUS?
The amendment increases the interest rate and extends the maturity date, aligning its financing terms with the company's current strategic needs.
What are related party transactions?
Related party transactions occur when directors or executives of a company engage in financial dealings with the company, which could present potential conflicts of interest.
What regulatory exemptions did ZYUS utilize?
ZYUS utilized exemptions under Multilateral Instrument 61-101, bypassing the need for a valuation and minority shareholder approval for the transactions.
What is ZYUS's commitment to innovation?
ZYUS is dedicated to developing novel cannabinoid-based therapies that provide alternatives to opioids, enhancing patient outcomes and safety.
